Contributing Authors | p. xiii |
Preface | p. xv |
Therapy | |
Staging Tables and Treatment Recommendations | p. 3 |
Hematologic Malignancies | p. 3 |
Acute Lymphoblastic Leukemia | p. 3 |
Acute Myelogenous Leukemia | p. 9 |
Chronic Lymphocytic Leukemia | p. 16 |
Hairy Cell Leukemia | p. 21 |
Chronic Myelogenous Leukemia | p. 24 |
Myelodysplastic Syndromes | p. 27 |
Plasma Cell Dyscrasias | p. 34 |
Hodgkin Lymphoma | p. 40 |
Non-Hodgkin Lymphoma | p. 46 |
Solid Tumors | p. 55 |
Malignant Melanoma | p. 55 |
Adult Central Nervous System Tumors | p. 61 |
Head and Neck Cancer | p. 66 |
Thyroid Cancer | p. 71 |
Breast Cancer | p. 78 |
Lung Cancer | p. 89 |
Esophageal Cancer | p. 96 |
Gastric Cancer | p. 101 |
Pancreatic Cancer | p. 106 |
Neuroendocrine Tumors of the Gastrointestinal Tract | p. 111 |
Hepatobiliary Cancer | p. 116 |
Colorectal Cancer | p. 126 |
Anal Cancer | p. 134 |
Adrenal Gland Cancer | p. 138 |
Bladder Cancer | p. 144 |
Renal Cell Carcinoma | p. 150 |
Prostate Cancer | p. 155 |
Penile Cancer | p. 162 |
Germ Cell Tumors | p. 166 |
Cervical Cancer | p. 174 |
Endometrial Cancer | p. 179 |
Gestational Trophoblastic Disease | p. 182 |
Epithelial Ovarian Cancer | p. 187 |
Ovarian Germ Cell Tumors | p. 192 |
Adult Soft Tissue Sarcomas | p. 194 |
Ewing Sarcoma and Primitive Neuroepithelial Tumors | p. 200 |
Neuroblastoma | p. 202 |
Osteosarcoma | p. 206 |
Retinoblastoma | p. 209 |
Rhabdomyosarcoma | p. 211 |
Wilms Tumor | p. 215 |
Cancer of Unknown Primary Origin | p. 218 |
HIV-Related Malignancies | p. 223 |
Chemotherapy Programs | p. 231 |
Acute Lymphocytic Leukemia | p. 231 |
Acute Myelogenous Leukemia | p. 235 |
Adult Central Nervous System Tumors | p. 238 |
Anal Cancer | p. 238 |
Bladder Cancer | p. 239 |
Breast Cancer | p. 241 |
Cervical Cancer | p. 247 |
Chronic Lymphocytic Leukemia | p. 248 |
Chronic Myelogenous Leukemia | p. 250 |
Colorectal Cancer | p. 251 |
Endocrine Cancer | p. 254 |
Endometrial Cancer | p. 254 |
Esophageal Cancer | p. 255 |
Gastric Cancer | p. 258 |
Gestational Trophoblastic Disease | p. 259 |
Hairy Cell Leukemia | p. 261 |
Head and Neck Cancer | p. 261 |
Hodgkin Disease | p. 263 |
Kaposi Sarcoma | p. 268 |
Lung Cancer--Non-Small Cell | p. 269 |
Lung Cancer--Small Cell | p. 272 |
Melanoma | p. 275 |
Mesothelioma | p. 276 |
Myelodysplastic Syndrome | p. 277 |
Myeloma | p. 277 |
Neuroendocrine Malignancies | p. 279 |
Non-Hodgkin Lymphoma | p. 280 |
Ovarian Cancer | p. 290 |
Pancreatic Cancer | p. 292 |
Penile Cancer | p. 293 |
Prostate Cancer | p. 293 |
Renal Cancer | p. 296 |
Sarcoma | p. 297 |
Testicular Cancer | p. 300 |
Pediatric Malignancies | p. 301 |
Toxicity Grading | p. 311 |
Chemotherapy Dose Modifications and Precautions | p. 381 |
DNA-Binding Drugs: Alkylating Agents | p. 381 |
Antimetabolites | p. 389 |
Antitumor Antibiotics and Related Agents | p. 394 |
Microtubule-Targeting Drugs | p. 399 |
DNA Topoisomerase Inhibitors | p. 400 |
Enzymes | p. 403 |
Hormonal Agents | p. 404 |
Biologic Response Modifiers | p. 407 |
Monoclonal Antibodies and Other Novel Agents | p. 407 |
Miscellaneous Agents | p. 412 |
Chemotherapeutic Agents | |
Drug Profiles | p. 419 |
Alemtuzumab | p. 419 |
Altretamine | p. 419 |
Amifostine | p. 419 |
Aminoglutethimide | p. 420 |
Anagrelide | p. 420 |
Anastrazole | p. 421 |
Arsenic Trioxide | p. 421 |
L-Asparaginase | p. 421 |
Peg-Asparaginase | p. 422 |
Azacitidine-NSC-102816 | p. 422 |
Azathioprine | p. 423 |
Bacillus Calmette-Guerin | p. 423 |
Bexarotene | p. 424 |
Bicalutamide | p. 424 |
Bleomycin | p. 425 |
Bortezomib | p. 425 |
Buserelin | p. 426 |
Busulfan | p. 426 |
Capecitabine | p. 426 |
Carboplatin | p. 427 |
Carmustine | p. 427 |
Carmustine-Impregnated Wafer | p. 428 |
Chlorambucil | p. 428 |
Cisplatin | p. 428 |
Cladribine | p. 429 |
Cyclophosphamide | p. 430 |
Cytarabine | p. 430 |
Cytarabine, Liposomal | p. 431 |
Dacarbazine | p. 431 |
Dactinomycin | p. 432 |
Darbopoietin Alfa | p. 432 |
Daunorubicin | p. 433 |
Daunorubicin, Liposomal | p. 433 |
Denileukin Diftitox | p. 434 |
Dexamethasone | p. 434 |
Dexrazoxane | p. 435 |
Docetaxel | p. 435 |
Doxorubicin | p. 436 |
Doxorubicin, Liposomal | p. 436 |
Epirubicin | p. 437 |
Erythropoietin | p. 437 |
Estramustine | p. 438 |
Etoposide and Etoposide Phosphate | p. 438 |
Exemestane | p. 439 |
Filgrastim/G-CSF | p. 439 |
Floxuridine | p. 440 |
Fludarabine | p. 441 |
5-Fluorouracil | p. 441 |
Fluoxymesterone | p. 442 |
Flutamide | p. 442 |
Gallium Nitrate | p. 442 |
Gefitinib | p. 443 |
Gemcitabine | p. 443 |
Gemtuzumab Ozogamicin | p. 444 |
Goserelin Acetate | p. 444 |
Hydroxyurea | p. 445 |
Ibritumomab Tiuxetan-Yttrium-90 | p. 445 |
Idarubicin | p. 446 |
Ifosfamide | p. 446 |
Imatinib Mesylate | p. 447 |
Interferon-[alpha] | p. 447 |
Interleukin-2 | p. 448 |
Irinotecan | p. 449 |
Isotretinoin | p. 450 |
Ketoconazole | p. 450 |
Letrozole | p. 451 |
Leucovorin Calcium | p. 451 |
Leuprolide Acetate | p. 452 |
Lomustine | p. 452 |
Mechlorethamine | p. 453 |
Medroxyprogesterone Acetate | p. 453 |
Megestrol Acetate | p. 454 |
Melphalan | p. 454 |
Mercaptopurine | p. 455 |
Mesna | p. 455 |
Methotrexate | p. 456 |
Mitomycin C | p. 456 |
Mitotane | p. 457 |
Mitoxantrone | p. 457 |
Nilutamide | p. 458 |
Octreotide, Octreotide Long-Acting | p. 458 |
Oprelvekin | p. 459 |
Oxaliplatin | p. 459 |
Paclitaxel | p. 460 |
Pamidronate | p. 461 |
Pegfilgrastim | p. 461 |
Pentostatin | p. 461 |
Plicamycin | p. 462 |
Prednisone | p. 462 |
Procarbazine | p. 463 |
Rituximab | p. 463 |
Sargramostim | p. 464 |
Streptozocin | p. 465 |
Tamoxifen | p. 465 |
Temozolomide | p. 465 |
Teniposide | p. 466 |
Thalidomide | p. 466 |
Thioguanine | p. 467 |
Thiotepa | p. 467 |
Topotecan | p. 468 |
Toremifene | p. 468 |
Trastuzumab | p. 469 |
Tretinoin | p. 469 |
Vinblastine | p. 470 |
Vincristine | p. 470 |
Vinorelbine | p. 471 |
Zoledronic Acid | p. 471 |
Symptom Control | |
Gastrointestinal Complaints | p. 475 |
Anorexia | p. 475 |
Constipation | p. 475 |
Diarrhea | p. 476 |
Nausea and Vomiting | p. 476 |
Mucositis | p. 482 |
Xerostomia | p. 490 |
Pain Assessment and General Treatment Guidelines | p. 493 |
Management of Selected Symptoms | p. 499 |
Suppression of Menses | p. 499 |
Cough | p. 499 |
Dyspnea | p. 499 |
Fever | p. 500 |
Hiccups | p. 500 |
Hot Flashes | p. 501 |
Fatigue | p. 501 |
Sleep-Wake Disturbances | p. 502 |
Appendix Table | p. 507 |
Subject Index | p. 511 |
Table of Contents provided by Rittenhouse. All Rights Reserved. |